Sacco, J. J., Harrington, K. J., Cervantes, A., Miguel, M. D., Alonso, G., Valpione, S., Olsson-Brown, A., Chan, T. Y., Nenclares, P., Leslie, I., Bommareddy, P., Kalbasi, A., Xie, B., Liu, D., Ulanet, D., Edavana, V., Vanasse, G., Aroldi, F., Skolariki, A., Middleton, M. R. (2026). RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2504